Related Experiment Video
Updated: Jan 10, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Disease Modulating Agents in Cirrhosis
Vinay Jahagirdar1, Jasmohan Singh Bajaj2
1Division of Gastroenterology, Hepatology & Nutrition, Department of Internal Medicine, Virginia Commonwealth University, 1200 East Broad Street, 14th Floor, Box 980341, Richmond, VA 23298, USA.
None:
The article discusses the progression and management of cirrhosis, emphasizing the importance of precise disease staging from compensated to decompensated states. This article evaluates the roles of beta-blockers, albumin, and rifaximin, emphasizing their potential as disease-modulating agents. By exploring these therapeutic strategies within clinical and research frameworks, the article reinforces the necessity for innovative treatments that can fundamentally alter the natural course of cirrhosis and improve patient outcomes.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...

